Aptalis, Cephalon win appeal against Amrix muscle relaxant patents
The two patents, owned by Aptalis and licensed to Cephalon, will expire in 2023 and 2025. Aptalis president John Fraher said, "Aptalis Pharmaceutical Technologies endeavors to offer to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.